Role of Apaf-1 in melanoma drug resistance and apoptosis [3]

Journal of Investigative Dermatology

Volumn 125, Issue 2, 2005, Pages 386-387

  Röckmann, Heike ^a,b   Schadendorf, Dirk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 9; DNA FRAGMENT; ETOPOSIDE; APAF1 PROTEIN, HUMAN; PROTEIN;

APOPTOSIS; CELL DEATH; DRUG RESISTANCE; ENZYME ACTIVATION; HUMAN; LETTER; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKIN TUMOR;

APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; PROTEINS; SKIN NEOPLASMS;

EID: 24344506204     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23821.x     Document Type: Letter

References (12)

1. Baldi A, Santini D, Russo P, et al: Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 13:93-97, 2004
2. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L: Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 22:451-455, 2003
3. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, Hoon DS: Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 64:2245-2250, 2004
4. Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendt B, Schadendorf D: Drug-resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 118:923-932, 2002
5. Jia L, Srinivasula SM, Liu FT, Newland AC, Fernandes-Alnemri T, Alnemri ES, Kelsey SM: Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 98:414-421, 2001
6. Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D: Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: Modulation of proto-oncogene expression. Anticancer Res 17:4359-4370, 1997
7. Lage H, Christmann M, Kern MA, Dietel M, Pick M, Kaina B, Schadendorf D: Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methyl-guanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance, Int J Cancer 80:744-750, 1999
8. Soengas MS, Capodieci P, Polsky D, et al: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409:207-211, 2001
9. Soengas MS, Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 22:3138-3151, 2003
10. Watanabe T, Hirota Y, Arakawa Y, et al: Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma. Brain Pathol 13:431-439, 2003
11. Wittig R, Nessling M, Will RD, et al: Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 62:6698-6705, 2002
12. Zanon M, Piris A, Bersani I, Vegetti C, Molla A, Scarito A, Anichini A: Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 64:7386-7394, 2004